Rapid health technology assessment of toripalimab combined with chemotherapy in the treatment of locally advanced or metastatic non-small cell lung cancer

YANG Yuping; ZHOU Yuan; TAI Qirui; SHI Mili; SHI Yijie; WANG Jieya; HU Huan; ZHANG Yuan; LIU Yi; WANG Yue

doi:10.6039/j.issn.1001-0408.2025.20.19

您当前的位置：

首页 >

文章列表页 >

Rapid health technology assessment of toripalimab combined with chemotherapy in the treatment of locally advanced or metastatic non-small cell lung cancer

更新时间：2025-10-25

- Rapid health technology assessment of toripalimab combined with chemotherapy in the treatment of locally advanced or metastatic non-small cell lung cancer
- ZHONGGUO YAOFANG Vol. 36, Issue 20, Pages: 2593-2598(2025)
- 作者机构：
  
  1.玉溪市人民医院药学部，云南玉溪　653100
  2.北京大学人民医院药学部，北京　100044
  3.玉溪市人民医院肿瘤中心，云南玉溪　653100
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2025.20.19
  CLC： R979.1
- Received：06 May 2025，
  
  Revised：2025-09-14，
  
  Accepted：15 September 2025，
  
  Published：30 October 2025
- 稿件说明：
移动端阅览
杨钰萍,周媛,台琪瑞,等.特瑞普利单抗联合化疗用于局部晚期或转移性NSCLC的快速卫生技术评估 [J].中国药房,2025,36(20):2593-2598.

YANG Yuping,ZHOU Yuan,TAI Qirui,et al.Rapid health technology assessment of toripalimab combined with chemotherapy in the treatment of locally advanced or metastatic non-small cell lung cancer[J].ZHONGGUO YAOFANG,2025,36(20):2593-2598.
杨钰萍,周媛,台琪瑞,等.特瑞普利单抗联合化疗用于局部晚期或转移性NSCLC的快速卫生技术评估 [J].中国药房,2025,36(20):2593-2598. DOI： 10.6039/j.issn.1001-0408.2025.20.19.

YANG Yuping,ZHOU Yuan,TAI Qirui,et al.Rapid health technology assessment of toripalimab combined with chemotherapy in the treatment of locally advanced or metastatic non-small cell lung cancer[J].ZHONGGUO YAOFANG,2025,36(20):2593-2598. DOI： 10.6039/j.issn.1001-0408.2025.20.19.

摘要

目的

评价特瑞普利单抗（Tor）联合化疗用于局部晚期或转移性非小细胞肺癌（NSCLC）的有效性、安全性和经济性。

方法

检索PubMed、the Cochrane Library、Embase、Web of Science、中国生物医学文献服务系统、中国知网、万方数据以及卫生技术评估（HTA）相关网站，收集Tor+化疗用于局部晚期或转移性NSCLC的HTA报告、系统评价/Meta分析和药物经济学研究，检索时限为建库或建站至2025年3月31日。提取资料、评价质量后，对纳入研究的结果进行描述性分析。

结果

共纳入11篇文献，包括系统评价/Meta分析5篇、药物经济学研究6篇。5篇系统评价/Meta分析中，高质量为2篇，中等、低和极低质量各1篇；6篇药物经济学研究的质量均良好。有效性方面，与化疗比较，Tor+化疗可显著延长患者的无进展生存期和总生存期（

＜0.05）；与伊匹木单抗+化疗、度伐利尤单抗、度伐利尤单抗+替西木单抗、舒格利单抗+化疗比较，Tor+化疗可显著延长患者的无进展生存期（

＜0.05）。安全性方面，Tor+化疗患者≥3级不良事件的发生率与化疗患者比较，差异无统计学意义（

＞0.05）；而与卡瑞利珠单抗+化疗、帕博利珠单抗+伊匹木单抗、纳武利尤单抗+化疗、阿替利珠单抗+化疗比较，Tor+化疗患者≥3级不良事件的发生率更低（

＜0.05）。经济性方面，与化疗比较，Tor+化疗具有经济学优势。

结论

与化疗、其他程序性死亡受体-1/程序性死亡受体配体-1抑制剂单用或联合化疗比较，Tor+化疗用于局部晚期或转移性NSCLC的有效性、安全性和经济性均较好。

Abstract

OBJECTIVE

To evaluate the efficacy， safety and cost-effectiveness of toripalimab （Tor） combined with chemotherapy （CT） in the treatment of locally advanced or metastatic non-small cell lung cancer （NSCLC）.

METHODS

PubMed， the Cochrane Library， Embase， Web of Science， CBM， CNKI， Wanfang Data， and Health Technology Assessment （HTA） related websites were searched to collect the HTA reports， systematic reviews/meta-analyses and pharmacoeconomic studies of Tor+CT in the treatment of locally advanced or metastatic NSCLC from database/website inception to March 31， 2025. After data extraction and quality evaluation， the results of the included studies were analyzed descriptively.

RESULTS

A total of eleven studies were included， involving five systematic reviews/meta-analyses， and six pharmacoeconomic studies. Among the five systematic reviews/meta-analyses， two were of high quality， while there was one each of moderate， low， and very low quality. All six pharmacoeconomic studies were of good quality. In terms of efficacy， compared with CT， Tor+CT significantly improved patients’ progression-free survival （PFS） and overall survival （

＜0.05）. In addition， compared with ipilimumab+CT， durvalumab， durvalumab+tremelimumab and sugemalimab+CT， Tor+CT could also improve the PFS （

＜0.05）. In terms of safety， there was no significant difference in the incidence of grade≥3 adverse events between patients receiving Tor+CT and CT （

＞0.05）； while Tor+CT had a lower incidence of grade≥3 adverse events， compared with camrelizumab+CT， pembrolizumab+ipilimumab， nivolumab+CT and atezolizumab+CT （

＜0.05）. In terms of cost-effectiveness， Tor+CT treatment had certain cost-effectiveness advantages， compared

with CT.

CONCLUSIONS

Compared with CT， other programmed death-1/programmed death-ligand 1 inhibitors alone， or their combination with CT， Tor+CT for the treatment of locally advanced or metastatic NSCLC has good efficacy， safety and cost-effectiveness.

关键词

Keywords

references

HAN B F ， ZHENG R S ， ZENG H M ， et al . Cancer incidence and mortality in China，2022 [J ] . J Natl Cancer Cent ， 2024 ， 4 （ 1 ）： 47 - 53 .

BOURREAU C ， TREPS L ， FAURE S ， et al . Therapeutic strategies for non-small cell lung cancer：experimental models and emerging biomarkers to monitor drug efficacies [J ] . Pharmacol Ther ， 2023 ， 242 ： 108347 .

中华医学会肿瘤学分会 . 中华医学会肺癌临床诊疗指南： 2024版 [J ] . 中华医学杂志， 2024 ， 104 （ 34 ）： 3175 - 3213 .

HUANG Q ， KEMNADE J ， CORNWELL L ， et al . Non-small cell lung cancer in the era of immunotherapy [J ] . Semin Oncol ， 2022 ， 49 （ 3/4 ）： 337 - 343 .

LU S ， WANG J ， YU Y ， et al . Tislelizumab plus chemotherapy as first-line treatment for locally advanced or metastatic nonsquamous NSCLC（RATIONALE 304）：a randomized phase 3 trial [J ] . J Thorac Oncol ， 2021 ， 16 （ 9 ）： 1512 - 1522 .

YANG Y P ， WANG Z H ， FANG J ， et al . Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC：a randomized，double-blind，phase 3 study（oncology program by InnovENT anti-PD-1-11） [J ] . J Thorac Oncol ， 2020 ， 15 （ 10 ）： 1636 - 1646 .

HERBST R S ， GIACCONE G ， DE MARINIS F ， et al . Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC [J ] . N Engl J Med ， 2020 ， 383 （ 14 ）： 1328 - 1339 .

MOK T S K ， WU Y L ， KUDABA I ， et al . Pembrolizumab versus chemotherapy for previously untreated，PD-L1- expressing，locally advanced or metastatic non-small-cell lung cancer（KEYNOTE-042）：a randomised，open-label，controlled，phase 3 trial [J ] . Lancet ， 2019 ， 393 （ 10183 ）： 1819 - 1830 .

中国临床肿瘤学会指南工作委员会 . 中国临床肿瘤学会（CSCO）非小细胞肺癌诊疗指南：2024 [M ] . 北京：人民卫生出版社， 2024 ： 134 - 174 .

唐惠林，门鹏，翟所迪 . 药物快速卫生技术评估方法及应用 [J ] . 临床药物治疗杂志， 2016 ， 14 （ 2 ）： 1 - 4 .

嵇承栋，朱琳懿，万悦竹，等 . 国际卫生技术评估机构协作网卫生技术评估报告清单解读 [J ] . 中国循证医学杂志， 2016 ， 16 （ 3 ）： 369 - 372 .

SHEA B J ， REEVES B C ， WELLS G ， et al . AMSTAR 2：a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions，or both [J ] . BMJ ， 2017 ， 358 ： j4008 .

HUSEREAU D ， DRUMMOND M ， AUGUSTOVSKI F ， et al . Consolidated health economic evaluation reporting standards 2022（CHEERS 2022）statement：updated re-porting guidance for health economic evaluations [J ] . BMJ ， 2022 ， 376 ： e067975 .

LANDRE T ， CHOUAÏD C ， SADAOUI N ， et al . Clinical benefit of anti-PD-1/PD-L1 plus chemotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic non-small cell lung cancer（NSCLC） [J ] . J Chemother ， 2024 ， 36 （ 8 ）： 675 - 681 .

杨艳青，陈伟，马璟婷，等 . PD-1/PD-L1抑制剂一线治疗晚期非鳞状非小细胞肺癌有效性及安全性的网状Meta分析 [J/OL ] . 中国胸心血管外科临床杂志， 2024 ： 1 - 10 .[ 2025-04-16 ] . https：//link.cnki.net/urlid/51.1492.R.20240416. 1153.010 https://link.cnki.net/urlid/51.1492.R.20240416.1153.010 . DOI： 10.7507/1007-4848.202312068 http://dx.doi.org/10.7507/1007-4848.202312068 .

ZHANG X W ， WU M ， CHEN J ， et al . Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer：a systematic review and network meta-analysis [J ] . Heliyon ， 2024 ， 10 （ 10 ）： e30809 .

FU W F ， XU M M ， SHI X Y ， et al . Comparison of the profiles of first-line PD-1/PD-L1 inhibitors for advanced NSCLC lacking driver gene mutations：a systematic review and Bayesian network meta-analysis [J ] . Ther Adv Chronic Dis ， 2023 ， 14 ： 20406223231189224 .

ZHAO M Y ， SHAO T H ， REN Y N ， et al . Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China：updated systematic review and network meta-analysis [J ] . Front Pharmacol ， 2022 ， 13 ： 910656 .

HUO G W ， LIU W J ， KANG S ， et al . Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer：a cost-effectiveness analysis [J ] . Front Pharmacol ， 2023 ， 14 ： 1131219 .

WANG H ， LONG Y C ， XU Y ， et al . Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer [J ] . Front Public Health ， 2023 ， 11 ： 1137255 .

ZHANG H X ， LI L F ， FENG L ， et al . Biomarkers-based cost-effectiveness of toripalimab plus chemotherapy for patients with treatment-naive advanced non-small cell lung cancer [J ] . Adv Ther ， 2023 ， 40 （ 11 ）： 4945 - 4956 .

ZHOU K X ， SHU P ， ZHENG H R ， et al . Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer（NSCLC）without EGFR or ALK driver mutations from the Chinese perspective [J ] . Front Pharmacol ， 2023 ， 14 ： 1133085

ZHANG M D ， XU K ， LIN Y T ， et al . Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China [J ] . Front Immunol ， 2023 ， 14 ： 1169752 .

ZHENG Z W ， ZHU G F ， CAO X Q ， et al . A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China [J ] . Expert Rev Clin Pharmacol ， 2023 ， 16 （ 3 ）： 267 - 273 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Rapid health technology assessment of inclisiran in the treatment of atherosclerotic cardiovascular disease with hypercholesterolemia

Rapid health technology assessment of serplulimab in the first-line treatment of small-cell lung cancer

Apixaban for the prevention and treatment of cancer-associated venous thromboembolism： a rapid health technology assessment

Rapid health technology assessment of tirzepatide for diabetes mellitus type 2 and long-term weight management

Calcium channel modulators in the treatment of diabetic peripheral neuropathic pain： a rapid health technology assessment

Related Author

LIU Ling

LI Wei

ZHANG Bo

ZHANG Qian

LIU Tianya

GAO Xing

WANG Xiaohui

HOU Yibing

Related Institution

Dept. of Anesthesiology， the Affiliated Hospital of Xuzhou Medical University

Dept. of Pharmacy， the Affiliated Hospital of Xuzhou Medical University

School of Pharmacy， Hebei Medical University

Medical Insurance Office， the Second Hospital of Hebei Medical University

Dept. of Pharmacy， the Second Hospital of Hebei Medical University

⁰